Lymphoma in China: Questions to Answer Before You Travel

Key Takeaways
- China’s top-ranked hospitals treat large lymphoma volumes, and the Fudan specialist reputation ranking names a small group of oncology centers among the country’s top 10 — a useful starting point for shortlisting, not a guarantee of outcome.
- A written second opinion or video consultation lets a Chinese hematology team review your existing biopsy reports and imaging before you book flights, which is often the cheapest way to test whether traveling makes sense.
- The honest barriers are real: public hospital outpatient registration generally cannot be reserved from abroad in advance, a face-to-face appointment usually precedes any admission, and large hospitals are hard to navigate without Chinese.
- Medical travelers use the S2 visa, not the M visa. Approval always depends on the latest embassy or consulate requirements and your supporting hospital documents.
If you are considering lymphoma in China, the first question to settle is not “which hospital is best” but “what can be decided before I travel.” A Chinese hematology team can review your pathology report, flow cytometry, cytogenetics, PET-CT and prior treatment history remotely and tell you whether your case is one they would treat differently — and whether an in-person visit is worth the trip. Everything else, from visa category to appointment logistics, follows from that answer.
This guide is written for international patients and families weighing that decision. It does not give medical advice, and it does not promise access, priority or outcomes. It explains what to prepare, what to ask, and where the practical friction lies.
The Problem: Lymphoma Care Is Rarely a Single Decision
Lymphoma is not one disease. Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphomas and dozens of subtypes behave differently, and the treatment pathway for each is defined by international guidelines such as those from the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO). Those guidelines are used in China too, which means the clinical question is usually not “is a different protocol available” but “is this center experienced with my subtype, at my stage, with my prior lines of therapy.”
The pain point for international patients is fragmentation. You may hold a diagnosis from one hospital, imaging from another, and a treatment history that spans years. Assembling that into a coherent package a new clinical team can act on takes time. Meanwhile, families are comparing systems across borders, often without knowing what a Chinese hospital will and will not do before the patient arrives.
There is also a structural reality worth naming early. At most Chinese public hospitals, outpatient registration is handled on the day, and surgical or inpatient admission generally follows an in-person consultation. International departments and VIP channels exist precisely to make scheduling more predictable for overseas patients, and they cost more. Understanding that distinction prevents wasted travel.
Why Chinese Oncology Centers Are Worth Evaluating
Specialist depth concentrated in a few cities
China has more than 35,000 hospitals. The Fudan Ranking of Chinese Hospitals, an annual reputation-based assessment, places only the top 100 in its comprehensive list, grouped into tiers from A++++ to A rather than numbered positions, and it also publishes specialist reputation rankings across 45 specialties, including oncology, with ranked top-10 lists. Those top-100 hospitals are concentrated in a handful of cities — Beijing, Shanghai and Guangzhou among them. For a patient with a rare lymphoma subtype, that concentration matters: experience with uncommon presentations tends to sit in high-volume referral centers.
Volume, trials and pathology capacity
Large Chinese cancer centers run substantial hematology and transplant programs and participate in clinical research. A practical question to ask any center is whether it has a dedicated hematopathology group that reviews outside biopsies, and whether it offers chimeric antigen receptor T-cell (CAR-T) therapy or autologous stem cell transplantation for eligible relapsed disease. Availability varies by hospital and by approval status, so it must be confirmed case by case rather than assumed.
Cost structure, stated carefully
Cost is the reason many patients look abroad, but lymphoma care resists tidy comparison. A treatment plan may combine chemotherapy, targeted agents, radiotherapy, stem cell support and long-term surveillance, and Chinese public hospitals typically require prepayment with insurance reimbursement handled afterward. Rather than quote a single figure, ask for an itemized estimate covering drugs, bed fees, laboratory and imaging, and any procedures. For context on how Chinese hospital pricing is organized and where international departments sit within it, our overview of medical treatment in China for international patients explains the two-track system.
What a Remote Lymphoma Review Actually Involves
Before any travel, a structured remote review can clarify whether a trip is justified. In practice it works in stages.
- Records package. Pathology report and, where possible, unstained slides or a block for re-review; immunohistochemistry and molecular results; staging PET-CT and CT images on disc; prior treatment regimens with dates and responses; current blood counts and organ function.
- Written second opinion. A Chinese specialty team reviews the material and returns written analysis, treatment suggestions and direction. This is for reference only, not a prescription, and it does not replace your treating physician.
- Video consultation. If questions remain, a live session with the specialty team allows you to explain symptoms and goals and hear recommendations directly, with interpretation where needed.
- Proxy consultation. Where a patient cannot travel yet, a designated city, hospital, department or specialist can be visited in person on the patient’s behalf using their materials, with registration and hospital card creation handled along the way. Any later admission remains subject to hospital rules.
This staged approach exists to reduce unnecessary early travel. It also gives you something concrete to compare: two written opinions side by side are far more useful than two brochures.
How to Judge Whether a Chinese Center Fits Your Case
Often the headline cost is lower, but lymphoma care is a multi-stage expense and comparisons are only meaningful against an itemized plan. Ask for a breakdown covering drugs, supportive care, imaging and any transplant or cell therapy, and factor in travel, accommodation and follow-up. We do not publish blanket savings figures because they would not be honest.
Seek care locally and immediately. Remote review is a planning tool, not emergency care, and no coordination service can substitute for urgent treatment near you. If your Chinese plan is already underway, tell your coordinator so timelines can be adjusted rather than forced.
Your Next Step
The core message is simple: decide what can be settled remotely before committing to travel, and treat any Chinese center’s opinion as one input alongside your current physician’s. We are China Medical Services, a coordination service — not a hospital, and we do not diagnose or treat. If a structured second opinion or a conversation about hospital options would help, you can request a free consultation and we will explain what your records would need to include.
This article is for general information only and is not medical advice. Treatment decisions should be made with qualified clinicians who have reviewed your individual case.
For more medical information and treatment options in China, visit chinamedservices.com (China Medical Services).